• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,708.52 -442.93
( -0.57%)
Global Indices
Nasdaq
52,169.86 -404.11
(-0.77%)
Dow Jones
7,480.34 -74.43
(-0.99%)
Hang Seng
63,887.74 -2,947.80
(-4.41%)
Nikkei 225
10,542.79 -57.58
(-0.54%)
Forex
USD-INR
96.36 0.10
(0.10%)
EUR-INR
110.37 0.25
(0.23%)
GBP-INR
130.11 0.62
(0.47%)
JPY-INR
0.59 0.00
(0.06%)

EQUITY - MARKET SCREENER

Dr Reddys Laboratories Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
500124
INE089A01031
377.9559391
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
DRREDDY
33
101066.72
EPS(TTM)
Face Value()
Div & Yield %
36.69
1
0.66
 

Sanofi India jumps after Nippon India MF adds stake
Jun 15,2026
According to exchange data, Nippon India Mutual Fund purchased 2.64 lakh shares, or 1.15% equity, of Sanofi India at Rs 3,150 per share through a bulk deal on 12 June 2026.

The shares were sold by HDFC Life Insurance Company, which offloaded 2.75 lakh shares, or 1.19% equity, at the same price.

As of the March 2026 quarter, Nippon India Small Cap Fund held an aggregate 3.79% stake in Sanofi India, while HDFC Life Insurance Company's Shareholders Solvency Margin Account owned 1.47% of the pharmaceutical company.

Sanofi India is engaged in the manufacture and marketing of pharmaceutical products and vaccines. On a standalone basis, Sanofi India's net profit declined 14.14% to Rs 102.60 crore while net sales declined 11.87% to Rs 472.30 crore in Q4 March 2026 over Q4 March 2025.